⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 30, 2024Expert Review of Pharmacoeconomics & Outcomes ResearchOpen Access

Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes

Mitsuhiro Nagano Sachiko Hyokai Kanae Togo Tendai Mugwagwa Akira Yuasa

View Full Paper

Ask AI

Bookmark

Share

Abstract

In Japan, medical expenses for COVID-19 treatment transitioned from full public funding support to out-of-pocket (OOP) payment by patients plus partial public support in October 2023, and public support fully ended in March 2024. This study evaluated the clinical and economic impacts of initiating OOP payments.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nagano et al. (2024) studied this question.

synapsesocial.com/papers/68e56395e2b3180350f00a59 https://doi.org/10.1080/14737167.2024.2410963

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Changes in Prescribing Patterns of Antiviral Drugs before and after Public Coverage Termination among Hospitalized COVID-19 Patients in Regional Hospitals in Japan: A Retrospective, Multicenter StudyCohort Study · 2026
2Variations in the perceived value of anti-SARS-CoV-2 therapeutics based on physicians’ clinical backgroundsOriginal Research · 2026
3Medical care cost dynamics during COVID-19 pandemic: financial implications for Japanese health insurance systemOriginal Research · 2026
4Socioeconomic and racial review of COVID-19 antiviral prescriptions: a large health system cohortCohort Study · 2026
5Out-of-Pocket Expenditure (OOPE) Among COVID-19 Patients by Insurance Status in a Quaternary Hospital in Karnataka, India2025 · 2 citations

More related papers

Physician characteristics associated with antiviral prescriptions for older adults with COVID-19 in Japan: an observational study2024
Nationwide Socioeconomic Evaluation of Direct‐Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 20232026
Inpatient Burden of COVID-19 in Japan: A Retrospective Cohort Study2024

More from Expert Review of Pharmacoeconomics & Outcomes Research

Cost-utility of expanded hypertension screening and treatment among adults covered by Peru’s Seguro integral de salud: a markov Model using national dataFri,
Machine learning in comparative effective research of pharmacological interventions: a scoping reviewTue,